SEC Form 4 · accession 0001209191-17-052627
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bowden
Officer — Chief Medical Officer
Period of report
Sep 11, 2017
Accepted (ET)
Sep 13, 2017 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Sep 11, 2017 | M | 6,000 | $35.16 | A | 6,881 | D | |
| Common stock | Sep 11, 2017 | S | 6,000 | $65.00 | D | 881 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F4 | $35.16 | Sep 11, 2017 | M | 6,000 | D | — | May 30, 2024 | Common stock | 6,000 | 109,000 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Includes 881 shares purchased through the Company's employee stock purchase plan.
- F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.